全文获取类型
收费全文 | 7581篇 |
免费 | 468篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 231篇 |
妇产科学 | 241篇 |
基础医学 | 1248篇 |
口腔科学 | 230篇 |
临床医学 | 748篇 |
内科学 | 1677篇 |
皮肤病学 | 185篇 |
神经病学 | 690篇 |
特种医学 | 150篇 |
外科学 | 667篇 |
综合类 | 49篇 |
一般理论 | 5篇 |
预防医学 | 685篇 |
眼科学 | 104篇 |
药学 | 500篇 |
中国医学 | 12篇 |
肿瘤学 | 570篇 |
出版年
2024年 | 7篇 |
2023年 | 64篇 |
2022年 | 152篇 |
2021年 | 289篇 |
2020年 | 166篇 |
2019年 | 233篇 |
2018年 | 246篇 |
2017年 | 206篇 |
2016年 | 229篇 |
2015年 | 238篇 |
2014年 | 275篇 |
2013年 | 403篇 |
2012年 | 645篇 |
2011年 | 600篇 |
2010年 | 343篇 |
2009年 | 292篇 |
2008年 | 532篇 |
2007年 | 542篇 |
2006年 | 485篇 |
2005年 | 519篇 |
2004年 | 398篇 |
2003年 | 370篇 |
2002年 | 322篇 |
2001年 | 38篇 |
2000年 | 33篇 |
1999年 | 50篇 |
1998年 | 49篇 |
1997年 | 43篇 |
1996年 | 43篇 |
1995年 | 41篇 |
1994年 | 30篇 |
1993年 | 34篇 |
1992年 | 20篇 |
1991年 | 20篇 |
1990年 | 12篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 12篇 |
1984年 | 8篇 |
1983年 | 9篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 9篇 |
1978年 | 3篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1947年 | 2篇 |
排序方式: 共有8076条查询结果,搜索用时 15 毫秒
71.
Latagliata R Breccia M Fazi P Iacobelli S Martinelli G Di Raimondo F Sborgia M Fabbiano F Pirrotta MT Zaccaria A Amadori S Caramatti C Falzetti F Candoni A Mattei D Morselli M Alimena G Vignetti M Baccarani M Mandelli F 《British journal of haematology》2008,143(5):681-689
This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years. Three hundred and one AML patients were randomized to receive DNR (45 mg/m(2) days 1-3) or DNX (80 mg/m(2) days 1-3) plus cytarabine (AraC; 100 mg/m(2) days 1-7). Patients in complete remission (CR) received a course of the same drugs as consolidation and then were randomized for maintenance with AraC+ all trans retinoic acid or no further treatment. Among 153 patients in the DNR arm, 78 (51.0%) achieved CR, 55 (35.9%) were resistant and 20 (13.1%) died during induction. Among 148 patients in the DNX arm, 73 (49.3%) achieved CR, 47 (31.8%) were resistant and 28 (18.9%) died during induction. Univariate analysis showed no difference as to induction results. After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis. DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses. 相似文献
72.
73.
Lumbrokinase from earthworm extract ameliorates second‐hand smoke‐induced cardiac fibrosis 下载免费PDF全文
74.
Garcia Cecilia C. Piotrkowski Bárbara Baz Plácida Poncino Daniel Benavides Javier Colombato Luis Toso María Laura Reyes Yantorno Silvina Descalzi Valeria Gondolesi Gabriel E. Fraga Cesar G. Cherñavsky Alejandra C. 《Digestive diseases and sciences》2022,67(7):3006-3016
Digestive Diseases and Sciences - Deregulation of immune response and oxidative stress contribute to nonalcoholic fatty liver disease (NAFLD) pathogenesis. Resistin is a physiological modulator of... 相似文献
75.
Abstract Currently available anticoagulants are effective in reducing the recurrence rate of venous thromboembolism (VTE). However,
anticoagulant treatment is associated with an increased risk for bleeding complications. Thus, anticoagulation has to be discontinued
when benefit of treatment no longer clearly outweigh its risks. The duration of anticoagulant treatment is currently framed
based on the estimated individual risk for recurrent VTE. The incidence of recurrent VTE can be estimated through a two-step
decision algorithm. Firstly, the features of the patient (gender), of the initial event (proximal or distal deep vein thrombosis
or pulmonary embolism), and the associated conditions (cancer, surgery, etc) provide essential information on the risk for
recurrence after anticoagulant treatment discontinuation. Secondly, at time of anticoagulant treatment discontinuation, d-dimer levels and residual thrombosis have been indicated as predictors of recurrent VTE. Current evidence suggests that the
risk of recurrence after stopping therapy is largely determined by whether the acute episode of VTE has been effectively treated
and by the patient’s intrinsic risk of having a new episode of VTE. All patients with acute VTE should receive oral anticoagulant
treatment for three months. At the end of this treatment period, physicians should decide for withdrawal or indefinite anticoagulation.
Based on intrinsic patient’s risk for recurrent VTE and for bleeding complications and on patient preference, selected patients
could be allocated to indefinite treatment with VKA with scheduled periodic re-assessment of the benefit from extending anticoagulation.
Alternative strategies for secondary prevention of VTE to be used after conventional anticoagulation are currently under evaluation.
Cancer patients should receive low molecular-weight heparin over warfarin in the long-term treatment of VTE. These patients
should be considered for extended anticoagulation at least until resolution of underlying disease.
Abbreviated abstract The risk for recurrent venous thromboembolism can be estimated through a two-step algorithm. Firstly, the features of the
patient (gender), of the initial event (proximal or distal deep vein thrombosis or pulmonary embolism), and the associated
conditions (cancer, surgery, etc) are essential to estimate the risk for recurrence after anticoagulant treatment discontinuation.
Secondly, a correlation has been shown between d-dimer levels and residual thrombosis at time of anticoagulant treatment discontinuation and the risk of recurrence. Currently
available anticoagulants are effective in reducing the incidence of recurrent venous thromboembolism, but they are associated
with an increased risk for bleeding complications. All patients with acute venous thromboembolism should receive oral anticoagulant
treatment for three months. At the end of this treatment period physicians should decide for definitive withdrawal or indefinite
anticoagulation with scheduled periodic re-assessment of the benefit from extending anticoagulation. 相似文献
76.
To define the specific role of IGF-I receptor (IGF-IR) in adipogenic and thermogenic differentiation of brown adipocytes during late fetal life, we have established immortalized brown adipocyte cell lines from fetuses of IGF-IR-deficient mice (IGF-IR(-/-)) as well as from wild-type mice (IGF-IR(+/+)). IGF-IR(-/-) cells showed an increased insulin sensitivity regarding insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation despite a substantial reduction in IRS-1 protein content. Furthermore, insulin-induced total and IRS-1-associated phosphatidylinositol 3-kinase activities were augmented in IGF-IR-deficient cells compared with wild-type cells. Downstream phosphatidylinositol 3-kinase activation of Akt, but not p70s6 kinase, were elicited at lower doses of insulin in IGF-IR(-/-) brown adipocytes. Activation of protein kinase Czeta by insulin was similar in both cell types as was insulin-induced glucose uptake. Treatment of wild-type brown adipocytes with insulin for 12 h up-regulated fatty acid synthase (FAS) and adipocyte determination and differentiation (ADD1/SREBP) mRNAs; this effect was impaired in the absence of IGF-IR. At the protein level, insulin increased FAS content and the amount of the mature form of adipocyte determination and differentiation (ADD1/SREBP) in the nucleus in wild-type cells, but not in IGF-IR(-/-) cells. Furthermore, 24 h of insulin stimulation induced the expression of both uncoupling protein-1 and CCAAT/enhancer-binding protein alpha (C/EBPalpha) in wild-type brown adipocytes; these effects were abolished in IGF-I-R(-/-) cells. Retrovirus-mediated reexpression of peroxisomal proliferator-activated receptor gamma (PPARgamma) in IGF-IR(-/-) brown adipocytes could overcome FAS mRNA impairment, bypassing insulin signaling. However, insulin further increased FAS mRNA expression in C/EBPalpha-IGF-IR(-/-) cells, but not in PPARgamma-IGF-IR(-/-) cells. In addition, fetal brown adipocytes lacking IGF-IR up-regulated uncoupling protein-1 expression in the absence of insulin when PPARgamma, but not C/EBPalpha, was overexpressed. These data provide strong evidence for a critical role of IGF-IR in the differentiation of the brown adipocyte phenotype in fetal life; this effect is mimicked by PPARgamma in an insulin-independent manner. 相似文献
77.
78.
Martin Stroedicke Yacine Bounab Nadine Strempel Konrad Klockmeier Sargon Yigit Ralf P. Friedrich Gautam Chaurasia Shuang Li Franziska Hesse Sean-Patrick Riechers Jenny Russ Cecilia Nicoletti Annett Boeddrich Thomas Wiglenda Christian Haenig Sigrid Schnoegl David Fournier Rona K. Graham Michael R. Hayden Stephan Sigrist Gillian P. Bates Josef Priller Miguel A. Andrade-Navarro Matthias E. Futschik Erich E. Wanker 《Genome research》2015,25(5):701-713
79.
80.
Stigma is a widely used concept in social science research and an extensive literature claims that stigmatisation contributes to numerous negative health outcomes. However, few studies compare groups that vary in the extent to which they are stigmatised and even fewer studies examine stigma's independent and mediating effects. This article addresses these gaps in a comparative study of perceived stigma and drug use among three low‐income feminised service occupations: sex work, food and alcoholic beverage serving, and barbering and hairstyling. An analysis of longitudinal data shows positive associations between sex work, perceived stigma, and socially less acceptable drug use (for example, heroin and cocaine), and that stigma mediates part of the link between sex work and the use of these drugs. Our overall findings suggest that perceived stigma is pronounced among those who work in the sex industry and negatively affects health independently of sex work involvement. 相似文献